Warning letter
Health Plus Inc.: warning letter of Dec 29, 2021
FDA warning letter 616877 · Division of Pharmaceutical Quality Operations IV
Key facts
| Reference number | 616877 |
|---|---|
| Company | Health Plus Inc. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Dec 29, 2021 |
| Posted date | Jan 25, 2022 |
| Issuing office | Division of Pharmaceutical Quality Operations IV |
| Product type | Drugs |
| CFR sections cited | 211.34, 211.204, 211.22(c), 211.100(a), 211.166(a), 211.165(e) |
| Inspection city | Chino |
| Inspection ZIP | 91710 |
| Inspection start date | Jun 23, 2021 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: